E A Strautmanis

City Clinical Emergency Hospital No. 1, Omsk, Russia.

1 publication 2025 – 2025 ORCID
RussiaIschemic StrokeFibrinolytic AgentsTissue Plasminogen ActivatorThrombolytic Therapy

What does E A Strautmanis research?

E A Strautmanis studies thrombolytic therapy, specifically a medication called Revelise (alteplase), which is used to treat ischemic strokes. This condition occurs when blood flow to the brain is blocked, leading to potentially severe outcomes. Their work centers on understanding how well Revelise works in real-world situations. This includes observing how the medication affects older patients and those with existing health issues, providing valuable insights for doctors and patients facing this critical medical emergency.

Key findings

  • In a study involving 2,202 patients, 49.9% experienced good outcomes upon discharge after treatment with Revelise.
  • The percentage of patients achieving good outcomes increased to 66.4% after 90 days of follow-up.
  • Revelise significantly reduces disability related to strokes even among older patients and those with other health conditions.

Frequently asked questions

Does Dr. Strautmanis study ischemic strokes?
Yes, Dr. Strautmanis focuses on ischemic strokes and how thrombolytic therapies like Revelise help treat this condition.
What treatments has Dr. Strautmanis researched?
Dr. Strautmanis has researched the medication Revelise (alteplase) for treating ischemic strokes.
Is Dr. Strautmanis's work relevant to older patients?
Yes, Dr. Strautmanis's research specifically includes older patients, demonstrating that Revelise can effectively reduce disabilities in this group.

Publications in plain English

[Thrombolytic Therapy for Ischemic Stroke with Revelise: Results of a Two-Year Follow-Up in the International PRIMA Study].

2025

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova

Shamalov NA, Khasanova DR, Marchenko SV, Soldatov MA, Azarova AG +46 more

Plain English
This study looked at how well and safely Revelise (alteplase), a medication for treating ischemic stroke (IS), works in real-life situations. It involved 2,202 patients, mostly around 68 years old, and found that nearly half (49.9%) of them had good outcomes when discharged, rising to 66.4% after 90 days. The results showed that Revelise effectively reduces stroke-related disabilities, even in older patients and those with other health issues. Who this helps: This benefits patients who suffer from ischemic strokes and the doctors treating them.

PubMed

Publication data sourced from PubMed . Plain-English summaries generated by AI. Not medical advice.